Lecanemab Offers New Hope in Alzheimer’s Fight, But NHS Access Remains Uncertain
A pioneering treatment for Alzheimer’s disease has renewed hopes of slowing the progression of the condition, following encouraging longer-term findings. However, despite receiving regulatory approval in the UK, access to the drug through the NHS remains unresolved.
Lecanemab, which became the first new Alzheimer’s treatment to receive a UK licence in almost 20 years when approved in August 2024, works by targeting amyloid protein deposits in the brain associated with the development of the disease.
Unlike existing dementia medications, which primarily help manage symptoms, lecanemab is designed to tackle one of the underlying biological processes involved in Alzheimer’s, potentially slowing the deterioration of memory, thinking and everyday functioning.
New findings presented in November 2026 suggest that the benefits of continued treatment may extend over five years.
The latest data, from the long-term extension of the international CLARITY AD clinical trial, indicate that people receiving lecanemab experienced a slower progression of the disease than would have been expected based on historical data from people with Alzheimer’s.
Researchers reported that treatment was associated with a 36 per cent reduction in the relative risk of progressing to the next stage of the disease compared with data from the Alzheimer’s Disease Neuroimaging Initiative.
However, patients continued to experience some deterioration, and further research will be needed to establish the treatment’s long-term effectiveness, safety and impact on quality of life.
NHS availability remains a major obstacle
Despite its UK regulatory approval, lecanemab is not currently available through the NHS in England, Wales or Scotland.
The Medicines and Healthcare products Regulatory Agency (MHRA) granted the medicine its licence in August 2024 after assessing its safety and effectiveness.
However, regulatory approval does not automatically mean that a treatment will be funded by the NHS.
In England and Wales, the National Institute for Health and Care Excellence (NICE) assesses whether medicines represent value for money for the health service, while the Scottish Medicines Consortium (SMC) undertakes a similar role in Scotland.
Both organisations have previously concluded that the clinical benefits of lecanemab do not sufficiently justify the substantial costs associated with introducing it into routine NHS care.
However, NICE’s decision is being reconsidered following successful appeals against aspects of its assessment, leaving the possibility of a revised recommendation open.
Alzheimer’s Research UK has highlighted that only a small proportion of people diagnosed with Alzheimer’s currently receive the detailed testing necessary to establish whether they would qualify for treatments such as lecanemab.
The charity argues that improving diagnostic services should be a priority regardless of whether new treatments become routinely available.
For those seeking treatment privately, specialist providers have begun offering lecanemab at selected clinics. However, advertised costs are estimated at between £60,000 and £80,000 annually, placing it beyond the financial reach of many families.
The debate surrounding lecanemab also raises wider questions about how the UK prepares for the next generation of dementia treatments.
Alzheimer’s Research UK estimates that dementia cost the UK economy approximately £42 billion in 2024, with unpaid care accounting for around half of the overall burden.
Social care represents another substantial component, with the costs associated with supporting someone with severe dementia estimated to be three times higher than those associated with mild dementia.
The charity forecasts that the overall economic cost of dementia could reach £90 billion by 2040 without significant progress in prevention, diagnosis and treatment.
It argues that assessments of new medicines should take greater account of their potential impact on families, unpaid carers and social care services, rather than concentrating solely on immediate NHS expenditure.

